Jazz Pharmaceuticals Delivers Strong Q2, Xywav Drives Higher Guidance, Morgan Stanley Says

MT Newswires Live08-04

Jazz Pharmaceuticals (JAZZ) delivered a strong Q2 as Xywav continued to outperform despite generic competition, prompting another increase in the company's full-year outlook, Morgan Stanley said in a research note Tuesday.

The investment firm said the increase reflects strong first hald execution and expected double-digit growth from Xywav and the combined epilepsy and oncology franchises.

The company's management said the slower-than-expected uptake of high-sodium generic competitors was a key reason for raising full-year guidance and expressed increased confidence in Xywav's long-term competitive position.

Morgan Stanley said Ziihera remains Jazz Pharmaceuticals' most important oncology growth driver. Management reiterated confidence ahead of the Aug. 25 PDUFA date for Ziihera as a first-line treatment for HER2-positive gastric and gastroesophageal adenocarcinoma and said interactions with the US FDA have been productive.

The investment firm raised Jazz's full-year 2026 revenue estimate to $4.77 billion from $4.47 billion. It also increased non-GAAP EPS estimates to $25.14 for 2026 and $28.85 for 2027 from $24.99 and $27.28.

Morgan Stanley has an overweight rating on Jazz Pharmaceuticals and raised its price target to $280 from $245.

Price: 251.98, Change: +0.40, Percent Change: +0.16

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656550303?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 23:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656550303","market":"nz","top_or_hot":-1,"title":"Jazz Pharmaceuticals Delivers Strong Q2, Xywav Drives Higher Guidance, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Jazz Pharmaceuticals (JAZZ) delivered a strong Q2 as Xywav continued to outperform despite generic competition, prompting another increase in the company's full-year outlook, Morgan Stanley said in a research note Tuesday.</p><p>The investment firm said the increase reflects strong first hald execution and expected double-digit growth from Xywav and the combined epilepsy and oncology franchises.</p><p>The company's management said the slower-than-expected uptake of high-sodium generic competitors was a key reason for raising full-year guidance and expressed increased confidence in Xywav's long-term competitive position.</p><p>Morgan Stanley said Ziihera remains Jazz Pharmaceuticals' most important oncology growth driver. Management reiterated confidence ahead of the Aug. 25 PDUFA date for Ziihera as a first-line treatment for HER2-positive gastric and gastroesophageal adenocarcinoma and said interactions with the US FDA have been productive.</p><p>The investment firm raised Jazz's full-year 2026 revenue estimate to $4.77 billion from $4.47 billion. It also increased non-GAAP EPS estimates to $25.14 for 2026 and $28.85 for 2027 from $24.99 and $27.28.</p><p>Morgan Stanley has an overweight rating on Jazz Pharmaceuticals and raised its price target to $280 from $245.</p><p>Price: 251.98, Change: +0.40, Percent Change: +0.16</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz Pharmaceuticals Delivers Strong Q2, Xywav Drives Higher Guidance, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz Pharmaceuticals Delivers Strong Q2, Xywav Drives Higher Guidance, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-04 23:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Jazz Pharmaceuticals (JAZZ) delivered a strong Q2 as Xywav continued to outperform despite generic competition, prompting another increase in the company's full-year outlook, Morgan Stanley said in a research note Tuesday.</p><p>The investment firm said the increase reflects strong first hald execution and expected double-digit growth from Xywav and the combined epilepsy and oncology franchises.</p><p>The company's management said the slower-than-expected uptake of high-sodium generic competitors was a key reason for raising full-year guidance and expressed increased confidence in Xywav's long-term competitive position.</p><p>Morgan Stanley said Ziihera remains Jazz Pharmaceuticals' most important oncology growth driver. Management reiterated confidence ahead of the Aug. 25 PDUFA date for Ziihera as a first-line treatment for HER2-positive gastric and gastroesophageal adenocarcinoma and said interactions with the US FDA have been productive.</p><p>The investment firm raised Jazz's full-year 2026 revenue estimate to $4.77 billion from $4.47 billion. It also increased non-GAAP EPS estimates to $25.14 for 2026 and $28.85 for 2027 from $24.99 and $27.28.</p><p>Morgan Stanley has an overweight rating on Jazz Pharmaceuticals and raised its price target to $280 from $245.</p><p>Price: 251.98, Change: +0.40, Percent Change: +0.16</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2T93.GBP","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656550303","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656550303","pubTimestamp":1785857956,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jazz Pharmaceuticals  delivered a strong Q2 as Xywav continued to outperform despite generic competition, prompting another increase in the company's full-year outlook, Morgan Stanley said in a research note Tuesday.The investment firm said the increase reflects strong first hald execution and expected double-digit growth from Xywav and the combined epilepsy and oncology franchises.The company's management said the slower-than-expected uptake of high-sodium generic competitors was a key reason for raising full-year guidance and expressed increased confidence in Xywav's long-term competitive position.Morgan Stanley said Ziihera remains Jazz Pharmaceuticals' most important oncology growth driver. Management reiterated confidence ahead of the Aug. 25 PDUFA date for Ziihera as a first-line treatment for HER2-positive gastric and gastroesophageal adenocarcinoma and said interactions with the US FDA have been productive.The investment firm raised Jazz's full-year 2026 revenue estimate to $4.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4007":"制药","BK4532":"文艺复兴科技持仓","JAZZ":"爵士制药","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC"},"translate_title":"摩根士丹利表示，爵士制药第二季度业绩强劲，Xywav 推动更高指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1},"content_text":"Jazz Pharmaceuticals (JAZZ) delivered a strong Q2 as Xywav continued to outperform despite generic competition, prompting another increase in the company's full-year outlook, Morgan Stanley said in a research note Tuesday.The investment firm said the increase reflects strong first hald execution and expected double-digit growth from Xywav and the combined epilepsy and oncology franchises.The company's management said the slower-than-expected uptake of high-sodium generic competitors was a key reason for raising full-year guidance and expressed increased confidence in Xywav's long-term competitive position.Morgan Stanley said Ziihera remains Jazz Pharmaceuticals' most important oncology growth driver. Management reiterated confidence ahead of the Aug. 25 PDUFA date for Ziihera as a first-line treatment for HER2-positive gastric and gastroesophageal adenocarcinoma and said interactions with the US FDA have been productive.The investment firm raised Jazz's full-year 2026 revenue estimate to $4.77 billion from $4.47 billion. It also increased non-GAAP EPS estimates to $25.14 for 2026 and $28.85 for 2027 from $24.99 and $27.28.Morgan Stanley has an overweight rating on Jazz Pharmaceuticals and raised its price target to $280 from $245.Price: 251.98, Change: +0.40, Percent Change: +0.16","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656550303","isCrawlerRequest":true}